Published September 23, 2026
The federal Dupixent T-cell lymphoma litigation took its next organizational step on September 10, 2026, when plaintiffs and defendants filed a joint case management report with Judge Zahid N. Quraishi in the District of New Jersey. The report addresses how the parties propose to structure plaintiffs' leadership, along with scheduling for discovery and future conferences, ahead of an initial case management conference set for October 1, 2026.
The Judicial Panel on Multidistrict Litigation centralized federal Dupixent lawsuits into MDL No. 3180 on June 4, 2026, consolidating cases that allege the eczema and asthma drug is linked to cutaneous T-cell lymphoma (CTCL) and other rare T-cell lymphomas. Judge Quraishi had directed the parties to meet by July 24 to identify areas of agreement before submitting their joint proposal.
The procedural filing came about three weeks after a Louisiana man filed a new product liability lawsuit against Regeneron Pharmaceuticals, Sanofi-Aventis U.S., and Genzyme Corporation in the same New Jersey federal court on August 20, 2026. According to reporting from Morris James LLP, the suit claims the companies failed to adequately warn that Dupixent use could cause or reignite a rare form of T-cell lymphoma.
Lawsuits in the MDL generally allege that Regeneron and Sanofi knew or should have known about a potential lymphoma risk associated with Dupixent's mechanism of action, but did not warn prescribers or patients. As the litigation moves into full case management, more plaintiffs are expected to file directly into the MDL rather than in their home districts.
If you or a loved one used Dupixent (dupilumab) and were later diagnosed with cutaneous T-cell lymphoma or another T-cell lymphoma, a free eligibility review can help determine whether you may qualify to file a claim. See Atumio's Dupixent Lawsuit case page for more information, or start your case review directly.